FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

Krystal Biotech (KRYS) shares rose 6.01% after the FDA expanded the label for its gene therapy, Vyjuvek, to include newborn dystrophic epidermolysis bullosa (DEB) patients and offer greater flexibility in wound dressing management. This update, supported by real-world safety and efficacy data, is anticipated by analysts, including William Blair, to significantly enhance Vyjuvek's market potential and long-term revenue, with current valuation potentially underestimating future growth.

Analysis

Krystal Biotech (KRYS) has secured a significant regulatory win with the U.S. FDA's approval of an expanded label for its gene therapy, Vyjuvek. The update broadens the eligible patient population for dystrophic epidermolysis bullosa (DEB) to include patients from birth, a critical demographic, and introduces greater flexibility by no longer requiring wound dressings to remain for 24 hours. This approval is underpinned by real-world data and an open-label extension study, reinforcing Vyjuvek's long-term safety and efficacy profile across all ages and supporting at-home application. The market reacted positively, with KRYS shares trading 6.01% higher to $152.32. Wall Street sentiment, as articulated by William Blair, is highly optimistic, citing the therapy's at-home dosing convenience and potential for a 'strong revenue tail,' particularly with a sizable Rest-of-World opportunity. Analysts further suggest that the company's current valuation may not fully account for Vyjuvek's long-term revenue potential and other pipeline catalysts expected within the next year.

Key Decisions for Investors

• The FDA label expansion de-risks Vyjuvek's commercial execution and materially expands its addressable market, representing a significant positive catalyst for Krystal Biotech's future revenue streams.
• Given analyst commentary that the current valuation does not fully reflect long-term potential, investors could view the stock as having further upside despite the recent price appreciation.
• Investors should monitor upcoming earnings reports for early signs of adoption under the expanded label and watch for management commentary on international expansion and other pipeline catalysts over the next 12 months.